Table 2. The recommended management of liver disease in UK clinical commissioning groups and health authorities in relation to national standards and guidelines.
| Area of UK | Using BSG-endorsed LFT pathwayn (%) | Using liver fibrosisassessmentn (%) | Using indirect serum fibrosis markersa n (%) | Using direct serum fibrosis markersb n (%) | Using transientelastographyc n (%) |
|---|---|---|---|---|---|
| Englandn = 135 | 50 (37%) | 52 (39%) | 56 (41%) | 18 (13%) | 26 (19%) |
| Northern Irelandn = 5 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Scotlandn = 12 | 8 (67%) | 8 (67%) | 9 (75%) | 6 (50%) | 7 (58%) |
| Walesn = 7 | 6 (86%) | 7 (100%) | 5 (71%) | 2 (29%) | 7 (100%) |
| UK totaln = 159 | 64 (40%) | 67 (42%) | 70 (44%) | 26 (16%) | 40 (25%) |
aIncluded use of Fib4 score, non-alcoholic fatty liver diease (NAFLD) fibrosis score and AST:ALT (aspartate aminotransferase: alanine aminotransferase) ratio (other options given); bAll but one response was for the enhanced liver fibrosis (ELF) test, single response hyaluronic acid.cAll using FibroScan.
BSG = British Society of Gastroenterology. LFT = liver function test. n = number of commissioning bodies